A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.

Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer. Screening triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), we identify a subset responsive to EGFR inhibition by gefitinib, which displays heterogeneous expression of wild-type EGFR. Deep single-cell RNA sequencing of 3,500 cells from an exceptional responder identified subpopulations displaying distinct biological features, where elevated EGFR expression was significantly enriched in a mesenchymal/stem-like cellular cluster. Sorted EGFRhi subpopulations exhibited enhanced stem-like features, including ALDH activity, sphere-forming efficiency, and tumorigenic and metastatic potential. EGFRhi cells gave rise to EGFRhi and EGFRlo cells in primary and metastatic tumors, demonstrating an EGFR-dependent expansion and hierarchical state transition. Similar tumorigenic EGFRhi subpopulations were identified in independent PDXs, where heterogeneous EGFR expression correlated with gefitinib sensitivity. This provides new understanding for an EGFR-dependent hierarchy in TNBC and for patient stratification for therapeutic intervention.

[1]  K. Mody,et al.  Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report , 2010, BMC Cancer.

[2]  Hai Hu,et al.  Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice , 2011, Breast Cancer Research.

[3]  Y. Yarden,et al.  The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors , 2015, Oncogene.

[4]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[5]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[6]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[7]  P. Petrow,et al.  Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Cole Trapnell,et al.  The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells , 2014, Nature Biotechnology.

[9]  A. Regev,et al.  Spatial reconstruction of single-cell gene expression , 2015, Nature Biotechnology.

[10]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[11]  J. Visvader,et al.  Mammary stem cells and the differentiation hierarchy: current status and perspectives , 2014, Genes & development.

[12]  R. Weinberg,et al.  Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells , 2017, Proceedings of the National Academy of Sciences.

[13]  Jeong Eon Lee,et al.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.

[14]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[15]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[16]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[17]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Gibson,et al.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.

[20]  P. Fasching,et al.  A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer , 2004, Breast Cancer Research and Treatment.

[21]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[23]  Chih-Yang Wang,et al.  Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells , 2015, Nature.

[24]  J. Baselga,et al.  Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[26]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[27]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[28]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[29]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.